Biberach, Germany, 16 April 2014 - Boehringer Ingelheim has received the Facility of the Year Award (FOYA) for Equipment Innovation in the project “ Aseptic Area 5 and Combi Line”, one of its aseptic drug product manufacturing areas at the company’s Biberach site. Boehringer Ingelheim received the award for the successful implementation of transparency, flexibility and innovative aseptic technologies in this state-of-the-art product manufacturing area. The U-shape line design provides flexible usage of individual processing steps while maximizing operational time of the area and allowing fast response to customer needs. The newly added drug product area provides best practice for aseptic processing in isolator technology. It delivers all dosage forms essential for the parenteral application of biopharmaceuticals, for example double chamber cartridges, for which there is a growing demand in immunology indications.
The Biberach site is the home of Europe’s largest facilities dedicated to biopharmaceutical development and manufacturing and delivers services both for Boehringer Ingelheim’s own biopharmaceuticals business and for its biopharmaceutical contract manufacturing business, Boehringer Ingelheim BioXcellence™. The site provides the entire value chain from cell line and process development to commercial scale cell culture manufacturing and finally to the aseptic production of various dosage forms of finished drug product. Embedded in the global biopharmaceutical manufacturing network of Boehringer Ingelheim, the Fill & Finish unit provides dosage forms like liquid or lyophilized vials, prefilled syringes, single and dual-chamber cartridges using modern aseptic technologies.
The Facility of the Year Award is an annual program recognizing state-of-the-art pharmaceutical manufacturing projects that utilize new and innovative technologies to enhance the delivery of a superior project, as well as reduce the cost of producing high-quality medicines sponsored by ISPE® (International Society for Pharmaceutical Engineering). www.facilityoftheyear.org/foya-winners-2014
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
All activities of the biopharmaceutical contract manufacturing are performed within the Boehringer Ingelheim Biopharmaceuticals GmbH, headquartered in Ingelheim, Germany. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its new brand Boehringer Ingelheim BioXcellence™. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience, the company has brought more than 20 biopharmaceutical products to the market. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle — transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.
More information: firstname.lastname@example.org